Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death

Purpose Effects of valproic acid (VPA), a histone deacetylase inhibitor, on the susceptibility to cell death induced by agonistic anti-Fas antibody were examined using four human osteosarcoma cell lines. Method Cell growth, secretion of soluble Fas, expression of cell-surface Fas, and sensitivity to...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cancer research and clinical oncology 2009-07, Vol.135 (7), p.879-889
Hauptverfasser: Yamanegi, Koji, Yamane, Junko, Hata, Masaki, Ohyama, Hideki, Yamada, Naoko, Kato-Kogoe, Nahoko, Futani, Hiroyuki, Nakasho, Keiji, Okamura, Haruki, Terada, Nobuyuki
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 889
container_issue 7
container_start_page 879
container_title Journal of cancer research and clinical oncology
container_volume 135
creator Yamanegi, Koji
Yamane, Junko
Hata, Masaki
Ohyama, Hideki
Yamada, Naoko
Kato-Kogoe, Nahoko
Futani, Hiroyuki
Nakasho, Keiji
Okamura, Haruki
Terada, Nobuyuki
description Purpose Effects of valproic acid (VPA), a histone deacetylase inhibitor, on the susceptibility to cell death induced by agonistic anti-Fas antibody were examined using four human osteosarcoma cell lines. Method Cell growth, secretion of soluble Fas, expression of cell-surface Fas, and sensitivity to Fas-mediated cell death were examined using cell proliferation assay, flow cytometry, enzyme-linked immunosorbent assay, and agonistic anti-Fas antibody, respectively. Results VPA suppressed the growth of all the four osteosarcoma cell lines and the secretion of soluble Fas from these cells. VPA showed no or slight suppressive effect on the expression of cell-surface Fas in the four osteosarcoma cell lines, but increased the sensitivity of three of four osteosarcoma cell lines to Fas-mediated cell death. Conclusion VPA enhances the susceptibility of human osteosarcoma cells to Fas-ligand-induced cell death by decreasing the secretion of soluble Fas and increasing the sensitivity to Fas-mediated cell death.
doi_str_mv 10.1007/s00432-008-0522-z
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20664309</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1733349301</sourcerecordid><originalsourceid>FETCH-LOGICAL-c423t-45f4d8bb6f3ac3883ee0fe911d9442c06e62a68a1ba1f576785a1047e98e87923</originalsourceid><addsrcrecordid>eNp9UcFu1TAQjBCIvhY-gAtYSOXUgNdOnOSIKgpIlTiUnq1NsulzlcTF61R6_So-EYf3RBEHTtaOZ8bjnSx7BfI9SFl9YCkLrXIp61yWSuUPT7INrAhoXT7NNhIqyEsF5ig7Zr6VaS4r9Tw7gkYa0xjYZD-vfO-WSdzjeBc8RjoTKLaOo59J9IQdxd2ITMLNW9e66MNZgrtACWMRtyR4naLzs_CDYD8u7UjiAlm0O7FdJkw4R_KMofMTio7GkQXOfXL8y8aFZDSzi-7exZ2IfrXIJ-pdytT_Vq1x4vZF9mzAkenl4TzJri8-fT__kl9--_z1_ONl3hVKx7woh6Kv29YMGjtd15pIDtQA9E1RqE4aMgpNjdAiDGVlqrpEkEVFTU111Sh9kr3b-6a1_FiIo50crzFwJr-wVWmDhZZNIr79h3jrlzCnbFYpWUIlNSQS7Eld8MyBBnsX3IRhZ0HatUu779KmLu3apX1ImtcH46VNi3hUHMpLhNMDAbnDcQg4d47_8BSUhdRq_Yra8zhdzTcUHhP-7_U3e9GA3uJNSMbXV0qClmC0MQr0L3uCwwI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>220517031</pqid></control><display><type>article</type><title>Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death</title><source>MEDLINE</source><source>SpringerNature Complete Journals</source><creator>Yamanegi, Koji ; Yamane, Junko ; Hata, Masaki ; Ohyama, Hideki ; Yamada, Naoko ; Kato-Kogoe, Nahoko ; Futani, Hiroyuki ; Nakasho, Keiji ; Okamura, Haruki ; Terada, Nobuyuki</creator><creatorcontrib>Yamanegi, Koji ; Yamane, Junko ; Hata, Masaki ; Ohyama, Hideki ; Yamada, Naoko ; Kato-Kogoe, Nahoko ; Futani, Hiroyuki ; Nakasho, Keiji ; Okamura, Haruki ; Terada, Nobuyuki</creatorcontrib><description>Purpose Effects of valproic acid (VPA), a histone deacetylase inhibitor, on the susceptibility to cell death induced by agonistic anti-Fas antibody were examined using four human osteosarcoma cell lines. Method Cell growth, secretion of soluble Fas, expression of cell-surface Fas, and sensitivity to Fas-mediated cell death were examined using cell proliferation assay, flow cytometry, enzyme-linked immunosorbent assay, and agonistic anti-Fas antibody, respectively. Results VPA suppressed the growth of all the four osteosarcoma cell lines and the secretion of soluble Fas from these cells. VPA showed no or slight suppressive effect on the expression of cell-surface Fas in the four osteosarcoma cell lines, but increased the sensitivity of three of four osteosarcoma cell lines to Fas-mediated cell death. Conclusion VPA enhances the susceptibility of human osteosarcoma cells to Fas-ligand-induced cell death by decreasing the secretion of soluble Fas and increasing the sensitivity to Fas-mediated cell death.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-008-0522-z</identifier><identifier>PMID: 19066961</identifier><identifier>CODEN: JCROD7</identifier><language>eng</language><publisher>Berlin/Heidelberg: Berlin/Heidelberg : Springer-Verlag</publisher><subject>Antibodies - pharmacology ; Antineoplastic agents ; Biological and medical sciences ; Bone cancer ; Bone Neoplasms - pathology ; Bone Neoplasms - secretion ; Cancer Research ; Cell Death - drug effects ; Cell Proliferation - drug effects ; Cellular biology ; Diseases of the osteoarticular system ; Down-Regulation - drug effects ; Drug Evaluation, Preclinical ; Drug Synergism ; Enzyme Inhibitors - pharmacology ; fas Receptor - immunology ; fas Receptor - secretion ; Hematology ; Histone Deacetylases - pharmacology ; Histones - metabolism ; Humans ; Inhibitor drugs ; Internal Medicine ; Medical sciences ; Medicine ; Medicine &amp; Public Health ; Oncology ; Original Paper ; Osteosarcoma - pathology ; Osteosarcoma - secretion ; Pharmacology. Drug treatments ; Solubility ; Tumor Cells, Cultured ; Tumors of striated muscle and skeleton ; Valproic Acid - pharmacology</subject><ispartof>Journal of cancer research and clinical oncology, 2009-07, Vol.135 (7), p.879-889</ispartof><rights>Springer-Verlag 2008</rights><rights>2009 INIST-CNRS</rights><rights>Springer-Verlag 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c423t-45f4d8bb6f3ac3883ee0fe911d9442c06e62a68a1ba1f576785a1047e98e87923</citedby><cites>FETCH-LOGICAL-c423t-45f4d8bb6f3ac3883ee0fe911d9442c06e62a68a1ba1f576785a1047e98e87923</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00432-008-0522-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00432-008-0522-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=21540322$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19066961$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yamanegi, Koji</creatorcontrib><creatorcontrib>Yamane, Junko</creatorcontrib><creatorcontrib>Hata, Masaki</creatorcontrib><creatorcontrib>Ohyama, Hideki</creatorcontrib><creatorcontrib>Yamada, Naoko</creatorcontrib><creatorcontrib>Kato-Kogoe, Nahoko</creatorcontrib><creatorcontrib>Futani, Hiroyuki</creatorcontrib><creatorcontrib>Nakasho, Keiji</creatorcontrib><creatorcontrib>Okamura, Haruki</creatorcontrib><creatorcontrib>Terada, Nobuyuki</creatorcontrib><title>Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><addtitle>J Cancer Res Clin Oncol</addtitle><description>Purpose Effects of valproic acid (VPA), a histone deacetylase inhibitor, on the susceptibility to cell death induced by agonistic anti-Fas antibody were examined using four human osteosarcoma cell lines. Method Cell growth, secretion of soluble Fas, expression of cell-surface Fas, and sensitivity to Fas-mediated cell death were examined using cell proliferation assay, flow cytometry, enzyme-linked immunosorbent assay, and agonistic anti-Fas antibody, respectively. Results VPA suppressed the growth of all the four osteosarcoma cell lines and the secretion of soluble Fas from these cells. VPA showed no or slight suppressive effect on the expression of cell-surface Fas in the four osteosarcoma cell lines, but increased the sensitivity of three of four osteosarcoma cell lines to Fas-mediated cell death. Conclusion VPA enhances the susceptibility of human osteosarcoma cells to Fas-ligand-induced cell death by decreasing the secretion of soluble Fas and increasing the sensitivity to Fas-mediated cell death.</description><subject>Antibodies - pharmacology</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Bone cancer</subject><subject>Bone Neoplasms - pathology</subject><subject>Bone Neoplasms - secretion</subject><subject>Cancer Research</subject><subject>Cell Death - drug effects</subject><subject>Cell Proliferation - drug effects</subject><subject>Cellular biology</subject><subject>Diseases of the osteoarticular system</subject><subject>Down-Regulation - drug effects</subject><subject>Drug Evaluation, Preclinical</subject><subject>Drug Synergism</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>fas Receptor - immunology</subject><subject>fas Receptor - secretion</subject><subject>Hematology</subject><subject>Histone Deacetylases - pharmacology</subject><subject>Histones - metabolism</subject><subject>Humans</subject><subject>Inhibitor drugs</subject><subject>Internal Medicine</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Oncology</subject><subject>Original Paper</subject><subject>Osteosarcoma - pathology</subject><subject>Osteosarcoma - secretion</subject><subject>Pharmacology. Drug treatments</subject><subject>Solubility</subject><subject>Tumor Cells, Cultured</subject><subject>Tumors of striated muscle and skeleton</subject><subject>Valproic Acid - pharmacology</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9UcFu1TAQjBCIvhY-gAtYSOXUgNdOnOSIKgpIlTiUnq1NsulzlcTF61R6_So-EYf3RBEHTtaOZ8bjnSx7BfI9SFl9YCkLrXIp61yWSuUPT7INrAhoXT7NNhIqyEsF5ig7Zr6VaS4r9Tw7gkYa0xjYZD-vfO-WSdzjeBc8RjoTKLaOo59J9IQdxd2ITMLNW9e66MNZgrtACWMRtyR4naLzs_CDYD8u7UjiAlm0O7FdJkw4R_KMofMTio7GkQXOfXL8y8aFZDSzi-7exZ2IfrXIJ-pdytT_Vq1x4vZF9mzAkenl4TzJri8-fT__kl9--_z1_ONl3hVKx7woh6Kv29YMGjtd15pIDtQA9E1RqE4aMgpNjdAiDGVlqrpEkEVFTU111Sh9kr3b-6a1_FiIo50crzFwJr-wVWmDhZZNIr79h3jrlzCnbFYpWUIlNSQS7Eld8MyBBnsX3IRhZ0HatUu779KmLu3apX1ImtcH46VNi3hUHMpLhNMDAbnDcQg4d47_8BSUhdRq_Yra8zhdzTcUHhP-7_U3e9GA3uJNSMbXV0qClmC0MQr0L3uCwwI</recordid><startdate>20090701</startdate><enddate>20090701</enddate><creator>Yamanegi, Koji</creator><creator>Yamane, Junko</creator><creator>Hata, Masaki</creator><creator>Ohyama, Hideki</creator><creator>Yamada, Naoko</creator><creator>Kato-Kogoe, Nahoko</creator><creator>Futani, Hiroyuki</creator><creator>Nakasho, Keiji</creator><creator>Okamura, Haruki</creator><creator>Terada, Nobuyuki</creator><general>Berlin/Heidelberg : Springer-Verlag</general><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7QP</scope><scope>7TM</scope></search><sort><creationdate>20090701</creationdate><title>Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death</title><author>Yamanegi, Koji ; Yamane, Junko ; Hata, Masaki ; Ohyama, Hideki ; Yamada, Naoko ; Kato-Kogoe, Nahoko ; Futani, Hiroyuki ; Nakasho, Keiji ; Okamura, Haruki ; Terada, Nobuyuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c423t-45f4d8bb6f3ac3883ee0fe911d9442c06e62a68a1ba1f576785a1047e98e87923</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Antibodies - pharmacology</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Bone cancer</topic><topic>Bone Neoplasms - pathology</topic><topic>Bone Neoplasms - secretion</topic><topic>Cancer Research</topic><topic>Cell Death - drug effects</topic><topic>Cell Proliferation - drug effects</topic><topic>Cellular biology</topic><topic>Diseases of the osteoarticular system</topic><topic>Down-Regulation - drug effects</topic><topic>Drug Evaluation, Preclinical</topic><topic>Drug Synergism</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>fas Receptor - immunology</topic><topic>fas Receptor - secretion</topic><topic>Hematology</topic><topic>Histone Deacetylases - pharmacology</topic><topic>Histones - metabolism</topic><topic>Humans</topic><topic>Inhibitor drugs</topic><topic>Internal Medicine</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Oncology</topic><topic>Original Paper</topic><topic>Osteosarcoma - pathology</topic><topic>Osteosarcoma - secretion</topic><topic>Pharmacology. Drug treatments</topic><topic>Solubility</topic><topic>Tumor Cells, Cultured</topic><topic>Tumors of striated muscle and skeleton</topic><topic>Valproic Acid - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yamanegi, Koji</creatorcontrib><creatorcontrib>Yamane, Junko</creatorcontrib><creatorcontrib>Hata, Masaki</creatorcontrib><creatorcontrib>Ohyama, Hideki</creatorcontrib><creatorcontrib>Yamada, Naoko</creatorcontrib><creatorcontrib>Kato-Kogoe, Nahoko</creatorcontrib><creatorcontrib>Futani, Hiroyuki</creatorcontrib><creatorcontrib>Nakasho, Keiji</creatorcontrib><creatorcontrib>Okamura, Haruki</creatorcontrib><creatorcontrib>Terada, Nobuyuki</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Nucleic Acids Abstracts</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yamanegi, Koji</au><au>Yamane, Junko</au><au>Hata, Masaki</au><au>Ohyama, Hideki</au><au>Yamada, Naoko</au><au>Kato-Kogoe, Nahoko</au><au>Futani, Hiroyuki</au><au>Nakasho, Keiji</au><au>Okamura, Haruki</au><au>Terada, Nobuyuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2009-07-01</date><risdate>2009</risdate><volume>135</volume><issue>7</issue><spage>879</spage><epage>889</epage><pages>879-889</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><coden>JCROD7</coden><abstract>Purpose Effects of valproic acid (VPA), a histone deacetylase inhibitor, on the susceptibility to cell death induced by agonistic anti-Fas antibody were examined using four human osteosarcoma cell lines. Method Cell growth, secretion of soluble Fas, expression of cell-surface Fas, and sensitivity to Fas-mediated cell death were examined using cell proliferation assay, flow cytometry, enzyme-linked immunosorbent assay, and agonistic anti-Fas antibody, respectively. Results VPA suppressed the growth of all the four osteosarcoma cell lines and the secretion of soluble Fas from these cells. VPA showed no or slight suppressive effect on the expression of cell-surface Fas in the four osteosarcoma cell lines, but increased the sensitivity of three of four osteosarcoma cell lines to Fas-mediated cell death. Conclusion VPA enhances the susceptibility of human osteosarcoma cells to Fas-ligand-induced cell death by decreasing the secretion of soluble Fas and increasing the sensitivity to Fas-mediated cell death.</abstract><cop>Berlin/Heidelberg</cop><pub>Berlin/Heidelberg : Springer-Verlag</pub><pmid>19066961</pmid><doi>10.1007/s00432-008-0522-z</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0171-5216
ispartof Journal of cancer research and clinical oncology, 2009-07, Vol.135 (7), p.879-889
issn 0171-5216
1432-1335
language eng
recordid cdi_proquest_miscellaneous_20664309
source MEDLINE; SpringerNature Complete Journals
subjects Antibodies - pharmacology
Antineoplastic agents
Biological and medical sciences
Bone cancer
Bone Neoplasms - pathology
Bone Neoplasms - secretion
Cancer Research
Cell Death - drug effects
Cell Proliferation - drug effects
Cellular biology
Diseases of the osteoarticular system
Down-Regulation - drug effects
Drug Evaluation, Preclinical
Drug Synergism
Enzyme Inhibitors - pharmacology
fas Receptor - immunology
fas Receptor - secretion
Hematology
Histone Deacetylases - pharmacology
Histones - metabolism
Humans
Inhibitor drugs
Internal Medicine
Medical sciences
Medicine
Medicine & Public Health
Oncology
Original Paper
Osteosarcoma - pathology
Osteosarcoma - secretion
Pharmacology. Drug treatments
Solubility
Tumor Cells, Cultured
Tumors of striated muscle and skeleton
Valproic Acid - pharmacology
title Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T04%3A47%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sodium%20valproate,%20a%20histone%20deacetylase%20inhibitor,%20decreases%20the%20secretion%20of%20soluble%20Fas%20by%20human%20osteosarcoma%20cells%20and%20increases%20their%20sensitivity%20to%20Fas-mediated%20cell%20death&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=Yamanegi,%20Koji&rft.date=2009-07-01&rft.volume=135&rft.issue=7&rft.spage=879&rft.epage=889&rft.pages=879-889&rft.issn=0171-5216&rft.eissn=1432-1335&rft.coden=JCROD7&rft_id=info:doi/10.1007/s00432-008-0522-z&rft_dat=%3Cproquest_cross%3E1733349301%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=220517031&rft_id=info:pmid/19066961&rfr_iscdi=true